BOLD - LogicBio Therapeutics Starts U.S. IPO Process
Quick Take
LogicBio Therapeutics (LOGC) intends to raise gross proceeds of $86.25 million from a U.S. IPO, according to an S-1 registration statement.
The firm is developing treatments for rare genetic diseases associated with the liver.
LOGC is an extremely early stage biopharma; I’ll provide an update when we learn more details from management.
Company & Technology
Foster City, California-based LogicBio Therapeutics was founded in 2014 to treat patients with unmet medical needs by precisely integrating corrective genes into their genome.
Management is headed by President, Director and CEO Frederic Chereau,